Releases

Date Title and Summary Additional Formats
Toggle Summary Veloxis Pharmaceuticals Announces Financial Calendar for 2016
Company Announcement no. 24/2015    To: NASDAQ OMX Copenhagen A/S                              Hørsholm, Denmark 16 November 2015   Veloxis Pharmaceuticals Announces Financial Calendar for 2016   Veloxis Pharmaceuticals A/S (OMX: VELO) today announced financial calendar for 2016.   9.
View HTML
Toggle Summary Veloxis Pharmaceuticals offentliggør finanskalendar for 2016
Selskabsmeddelelse nr. 24/2015    Til: NASDAQ OMX Copenhagen A/S                               Hørsholm, 16 November 2015      Veloxis Pharmaceuticals offentliggør finanskalendar for 2016   Veloxis Pharmaceuticals A/S (OMX: VELO) har i dag offentliggjort finanskalendar for 2016.
View HTML
Toggle Summary Veloxis Pharmaceuticals announces financial results for the first nine months of 2015
Company Announcement no. 23/2015   To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 11 November, 2015     Veloxis Pharmaceuticals announces financial results for the first nine months of 2015   Highlights:   On 30 September, 2015, Veloxis had cash and cash equivalents of DKK 157.6 million , and the
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 3. kvartal 2015 — resultater fra 1. januar til 30. september 2015
Investor service meddelelse nr. 5/2015   Til: NASDAQ OMX København                                     Hørsholm, den 4 november 2015       Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 3. kvartal 2015 — resultater fra 1.
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for the third Quarter 2015 — results from 1 January to 30 September, 2015
Investor service announcement no. 5/2015    To: NASDAQ OMX Copenhagen                         Hørsholm, Denmark, 4 November, 2015      Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for the third Quarter 2015 — results from 1 January to 30 September, 2015   Veloxis
View HTML
Toggle Summary Veloxis Establishes Sponsored Level 1 ADR Program in U.S.
Company Announcement no. 22/2015   To: NASDAQ OMX Copenhagen A/S                            Hørsholm, Denmark 14 October 2015      Veloxis Establishes Sponsored Level 1 ADR Program in U.S.   Goals of program are to simplify trading for U.S. investors and develop new investors   ADR trades under
View HTML
Toggle Summary Veloxis etablerer sponsoreret Niveau 1 ADR program i U.S.A.
Selskabsmeddelelse nr. 22/2015   Til: NASDAQ OMX Copenhagen A/S                            Hørsholm, 14 oktober 2015      Veloxis etablerer sponsoreret Niveau 1 ADR program i U.S.A.   Programmets formål er at forenkle handel for amerikanske investorer og tiltrække nye investorer ADR'er vil blive
View HTML
Toggle Summary Veloxis Announces Publication of Phase III-b STRATO Study of Envarsus® XR Demonstrating Reduction in Hand Tremors Compared to Twice-Daily Tacrolimus in Kidney Transplant Patients
Investor service announcement no. 5/2015   To: NASDAQ OMX Copenhagen A/S                      Hørsholm, Denmark, 21 September 2015    Veloxis Announces Publication of Phase III-b STRATO Study of Envarsus ® XR Demonstrating Reduction in Hand Tremors Compared to Twice-Daily Tacrolimus in Kidney
View HTML
Toggle Summary Veloxis increases share capital in connection with exercise of warrants
Company Announcement no. 21/2015    To: NASDAQ OMX Copenhagen A/S                            Hørsholm, Denmark, 15 September 2015    Veloxis increases share capital in connection with exercise of warrants   Veloxis Pharmaceuticals A/S announces that the company's capital has been increased by
View HTML
Toggle Summary Veloxis udsteder nye aktier i forbindelse med udnyttelse af warrants
Selskabsmeddelelse nr. 21/2015     Til: NASDAQ OMX Copenhagen A/S                                     Hørsholm, den 15. september 2015     Veloxis udsteder nye aktier i forbindelse med udnyttelse af warrants   Veloxis Pharmaceuticals A/S meddeler hermed, at selskabet har forhøjet sin aktiekapital
View HTML
Toggle Summary Envarsus® XR Data to be Presented at European Society of Transplantation
Investor service announcement no. 4/2015     To: NASDAQ OMX Copenhagen A/S                      Hørsholm, Denmark, 10 September 2015      Envarsus ® XR Data to be Presented at European Society of Transplantation   Full Data Set of ASTCOFF Study Presented Demonstrating Differentiated
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S etablerer warrantordning
Selskabsmeddelelse nr. 20/2015    Til: NASDAQ OMX Copenhagen A/S                                      Hørsholm, den 27. august 2015     Veloxis Pharmaceuticals A/S etablerer warrantordning   Bestyrelsen i Veloxis Pharmaceuticals A/S har i dag besluttet at etablere en warrantordning for nye
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S establishes new Warrant Programme
Company Announcement no. 20/2015     To: NASDAQ OMX Copenhagen A/S                             Hørsholm, Denmark, 27 August 2015     Veloxis Pharmaceuticals A/S establishes new Warrant Programme   Today, the Board of Directors of Veloxis has decided to establish a new warrant programme for new
View HTML
Toggle Summary Veloxis Pharmaceuticals announces financial results for the first six months of 2015 and improves the full year outlook
Company Announcement no. 19/2015   To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 26 August, 2015     Veloxis Pharmaceuticals announces financial results for the first six months of 2015 and improves the full year outlook   Highlights:   On 14 August, 2015 Envarsus® XR was granted Orphan Drug
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 2. kvartal 2015 — resultater fra 1. januar til 30. juni 2015
Investor service meddelelse nr. 3/2015    Til: NASDAQ OMX København                                     Hørsholm, den 20 august 2015      Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 2. kvartal 2015 — resultater fra 1.
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for the second Quarter 2015 — results from 1 January to 30 June, 2015
Investor service announcement no. 3/2015   To: NASDAQ OMX Copenhagen                         Hørsholm, Denmark, 20 August, 2015      Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for the second Quarter 2015 — results from 1 January to 30 June, 2015   Veloxis
View HTML
Toggle Summary Veloxis Pharmaceuticals Envarsus® XR Granted Orphan Drug Status by U.S. Food and Drug Administration for Kidney Transplant Rejection Prophylaxis
Company Announcement no. 18/2015     To: NASDAQ OMX Copenhagen A/S                           Hørsholm, Denmark, 14 August 2015     Veloxis Pharmaceuticals Envarsus ® XR Granted Orphan Drug Status by U.S. Food and Drug Administration for Kidney Transplant Rejection Prophylaxis     Veloxis
View HTML
Toggle Summary Veloxis Pharmaceuticals Envarsus® XR er tildelt Orphan Drug status af det amerikanske FDA til forebyggelse af nyretransplantatafstødning
Selskabsmeddelelse nr. 18/2015     Til: NASDAQ OMX Copenhagen A/S                           Hørsholm, 14. august 2015     Veloxis Pharmaceuticals Envarsus ® XR er tildelt Orphan Drug status af det amerikanske FDA  til forebyggelse af nyretransplantatafstødning   Veloxis Pharmaceuticals A/S (OMX:
View HTML
Toggle Summary Veloxis Announces U.S. FDA Approval of Envarsus® XR for Treatment of Kidney Transplant Patients
Company Announcement no. 17/2015     To: NASDAQ OMX Copenhagen A/S                      Hørsholm, Denmark, July 10, 2015     Veloxis Announces U.S. FDA Approval of Envarsus ® XR for Treatment of Kidney Transplant Patients   Envarsus ® XR is Indicated for Patients Converted from Tacrolimus
View HTML
Toggle Summary Veloxis offentliggør amerikansk FDA godkendelse af Envarsus® XR til behandling af nyretransplantationspatienter
Selskabsmeddelelse nr. 17/2015   Til: NASDAQ OMX Copenhagen A/S                      Hørsholm, 10 juli 2015      Veloxis offentliggør amerikansk FDA godkendelse af Envarsus ® XR til behandling af nyretransplantationspatienter   Envarsus ® XR er indikeret for patienter konverteret fra
View HTML
Toggle Summary Envarsus® XR Demonstrates Differentiated Pharmacokinetic Profile Compared to Twice-Daily Prograf® or Once-Daily Astagraf XL® in Stable Kidney Transplant Patients
Company Announcement no. 16/2015     To: NASDAQ OMX Copenhagen A/S                      Hørsholm, Denmark, June 24, 2015     Envarsus ® XR Demonstrates Differentiated Pharmacokinetic Profile Compared to Twice-Daily Prograf ® or Once-Daily Astagraf XL ® in Stable Kidney Transplant Patients   Veloxis
View HTML
Toggle Summary Envarsus® XR udviser differentieret farmakokinetisk profil sammenlignet med to-gange-daglig Prograf® eller én-gang-daglig Astagraf XL® i stabile nyretransplantationspatienter
Selskabsmeddelelse nr. 16/2015     Til: NASDAQ OMX Copenhagen A/S                                Hørsholm, den 24. juni 2015     Envarsus ® XR udviser differentieret farmakokinetisk profil sammenlignet med to-gange-daglig Prograf ® eller én-gang-daglig Astagraf XL ® i stabile
View HTML
Toggle Summary Afgørelse fra amerikansk distriktsdomstol i Veloxis retssag
Selskabsmeddelelse nr. 15/2015     Til: NASDAQ OMX Copenhagen A/S                      Hørsholm, 12. juni 2015       Afgørelse fra amerikansk distriktsdomstol i Veloxis retssag   Amerikansk distriktsdomstol afgør, at Envarsus ® XR er afskåret for de novo anvendelse Veloxis indsender
View HTML
Toggle Summary U.S. District Court Rules in Veloxis Litigation
Company Announcement no. 15/2015     To: NASDAQ OMX Copenhagen A/S                      Hørsholm, Denmark, 12 June 2015      U.S. District Court Rules in Veloxis Litigation   U.S. District Court rules that Envarsus ® XR is blocked in de novo setting Veloxis submits labeling for use in conversion
View HTML
Toggle Summary Warrant Programme - Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants
Company Announcement no. 14/2015     To: NASDAQ OMX Copenhagen A/S                             Hørsholm, Denmark, 3 June 2015      Warrant Programme - Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants   Veloxis Pharmaceuticals A/S announces that the company's
View HTML
Toggle Summary Warrantprogram - Veloxis Pharmaceuticals A/S udsteder nye aktier i forbindelse med udnyttelse af warrants
Selskabsmeddelelse nr. 14/2015   Til: NASDAQ OMX Copenhagen A/S                                      Hørsholm, den 3. juni 2015    Warrantprogram - Veloxis Pharmaceuticals A/S udsteder nye aktier i forbindelse med udnyttelse af warrants   Veloxis Pharmaceuticals A/S meddeler hermed, at selskabet
View HTML
Toggle Summary Veloxis Pharmaceuticals announces financial results for the first three months of 2015
Company Announcement no. 13/2015   To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 20 May, 2015     Veloxis Pharmaceuticals announces financial results for the first three months of 2015   Highlights:   Veloxis has announced that once-daily Envarsus® XR, an investigational new drug under FDA
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for the first Quarter 2015 — results from 1 January to 31 March, 2015
Investor service announcement no. 2/2015   To: NASDAQ OMX Copenhagen                         Hørsholm, Denmark, 12 May, 2015      Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for the first Quarter 2015 — results from 1 January to 31 March, 2015   Veloxis
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 1. kvartal 2015 — resultater fra 1. januar til 31. marts 2015
Investor service meddelelse nr. 2/2015   Til: NASDAQ OMX København                                     Hørsholm, den 12 maj 2015   Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 1. kvartal 2015 — resultater fra 1.
View HTML
Toggle Summary Envarsus® XR Demonstrates Improved Pharmacokinetic Profile in African-American Transplant Recipients
Company Announcement no. 12/2015     To: NASDAQ OMX Copenhagen A/S                      Hørsholm, Denmark, 4 May 2015      Envarsus ® XR Demonstrates Improved Pharmacokinetic Profile in African-American Transplant Recipients   Data presented at the American Transplant Congress   Veloxis
View HTML
Toggle Summary Envarsus® XR viser forbedret farmakokinetisk profil i afroamerikanske transplantatmodtagere
Selskabsmeddelelse nr. 12/2015     Til: NASDAQ OMX Copenhagen A/S                                  Hørsholm, 4. maj 2015      Envarsus ® XR viser forbedret farmakokinetisk profil i afroamerikanske transplantatmodtagere   Data præsenteret på American Transplant Congress   Veloxis Pharmaceuticals A/S
View HTML
Toggle Summary Warrant Programme - New Articles of Association
Company Announcement no. 11/2015     To: NASDAQ OMX Copenhagen A/S                                     Hørsholm, Denmark, 10 April 2015      Warrant Programme - New Articles of Association   In accordance with its authorisation pursuant to Section 5A of the Articles of Association, the Board of
View HTML
Toggle Summary Warrantordning - Nye vedtægter
Selskabsmeddelelse nr. 11/2015     Til: NASDAQ OMX Copenhagen A/S                                             Hørsholm, den 10. april 2015       Warrantordning - Nye vedtægter     Bestyrelsen i Veloxis Pharmaceuticals A/S har i henhold til bemyndigelsen i vedtægternes § 5A, den 27.
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S establishes new Warrant Programme
Company Announcement no. 10/2015     To: NASDAQ OMX Copenhagen A/S                             Hørsholm, Denmark, 27 March 2015     Veloxis Pharmaceuticals A/S establishes new Warrant Programme   Today, the Board of Directors of Veloxis has decided to establish a new warrant programme for members
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S etablerer warrantordning
Selskabsmeddelelse nr. 10/2015    Til: NASDAQ OMX Copenhagen A/S                                      Hørsholm, den 27. marts 2015    Veloxis Pharmaceuticals A/S etablerer warrantordning   Bestyrelsen i Veloxis Pharmaceuticals A/S har i dag besluttet at etablere en warrantordning for medlemmer af
View HTML
Toggle Summary Warrant Programme - Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants
Company Announcement no. 9/2015     To: NASDAQ OMX Copenhagen A/S                             Hørsholm, Denmark, 27 March 2015      Warrant Programme - Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants   Veloxis Pharmaceuticals A/S announces that the company's
View HTML
Toggle Summary Warrantprogram - Veloxis Pharmaceuticals A/S udsteder nye aktier i forbindelse med udnyttelse af warrants
Selskabsmeddelelse nr. 9/2015     Til: NASDAQ OMX Copenhagen A/S                                      Hørsholm, den 27. marts 2015     Warrantprogram - Veloxis Pharmaceuticals A/S udsteder nye aktier i forbindelse med udnyttelse af warrants   Veloxis Pharmaceuticals A/S meddeler hermed, at
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S - Forløb af ordinær generalforsamling
Selskabsmeddelelse nr. 8/2015     Til: NASDAQ OMX Copenhagen A/S                                            Hørsholm, den 26. marts 2015     Veloxis Pharmaceuticals A/S - Forløb af ordinær generalforsamling   Resumé: På Veloxis Pharmaceuticals A/S' ordinære generalforsamling afholdt tidligere i dag
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting
Company Announcement no. 8/2015     To: NASDAQ OMX Copenhagen A/S                      Hørsholm, Denmark, March 26, 2015     Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting   Summary: At Veloxis Pharmaceuticals A/S' Annual General Meeting held earlier today, All proposals from the
View HTML
Toggle Summary Indkaldelse til ordinær generalforsamling
Selskabsmeddelelse nr. 7/2015     Til: NASDAQ OMX Copenhagen A/S                                 Hørsholm, 4. marts 2015   Indkaldelse til ordinær generalforsamling Bestyrelsen for Veloxis Pharmaceuticals A/S, CVR-nr. 26 52 77 67 ("Selskabet"), indkalder hermed til Selskabets ordinære
View HTML
Toggle Summary Notice to Convene Annual General Meeting
Company Announcement no. 7/2015     To: NASDAQ OMX Copenhagen A/S                                        Hørsholm, Denmark, 4 March, 2015     Notice to Convene Annual General Meeting   The board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 (" the Company"), hereby convenes the
View HTML
Toggle Summary Warrantordning - Nye vedtægter
Selskabsmeddelelse nr. 6/2015     Til: NASDAQ OMX Copenhagen A/S                                          Hørsholm, den 3. marts 2015       Warrantordning - Nye vedtægter     Bestyrelsen i Veloxis Pharmaceuticals A/S har i henhold til bemyndigelsen i vedtægternes § 5A, den 3.
View HTML
Toggle Summary Warrant Programme - New Articles of Association
Company Announcement no. 6/2015   To: NASDAQ OMX Copenhagen A/S                                  Hørsholm, Denmark, 3 March 2015      Warrant Programme - New Articles of Association     In accordance with its authorisation pursuant to Section 5A of the Articles of Association, the Board of
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S etablerer warrantordning
Selskabsmeddelelse nr. 5/2015     Til: NASDAQ OMX Copenhagen A/S                                      Hørsholm, den 3 marts 2015       Veloxis Pharmaceuticals A/S etablerer warrantordning   Bestyrelsen i Veloxis Pharmaceuticals A/S har i dag besluttet at etablere en warrantordning for alle
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S establishes new Warrant Programme
Company Announcement no. 5/2015     To: NASDAQ OMX Copenhagen A/S                             Hørsholm, Denmark, 3 March 2015     Veloxis Pharmaceuticals A/S establishes new Warrant Programme   Today, the Board of Directors of Veloxis has decided to establish a new warrant programme for all
View HTML
Toggle Summary Veloxis Pharmaceuticals offentliggør årsrapport 2014
Selskabsmeddelelse nr. 4/2015   Til: NASDAQ OMX Copenhagen A/S         Hørsholm, 3. marts 2015     Veloxis Pharmaceuticals offentliggør årsrapport 2014   Veloxis Pharmaceuticals A/S (OMX:VELO) (‘Veloxis') har i dag offentliggjort årsrapporten for Veloxis Pharmaceuticals A/S for året 2014.
View HTML
Toggle Summary Veloxis Pharmaceuticals publishes Annual Report 2014
Company Announcement no. 4/2015   To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 3 March 2015     Veloxis Pharmaceuticals p ublishes Annual Report 2014   Veloxis Pharmaceuticals A/S (OMX: VELO) (‘Veloxis') today published the annual report of Veloxis Pharmaceuticals A/S for the financial year
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Annual report 2014 — results from 1 January to 31 December, 2014
Investor service announcement no. 1/2015    To: NASDAQ OMX Copenhagen                         Hørsholm, Denmark, 24 February, 2015    Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Annual report 2014 — results from 1 January to 31 December, 2014   Veloxis Pharmaceuticals A/S (OMX:
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af årsrapporten 2014 — resultater fra 1. januar til 31. december 2014
Investor service meddelelse nr. 1/2015   Til: NASDAQ OMX København                                    Hørsholm, den 24 februar 2015   Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af årsrapporten 2014 — resultater fra 1. januar til 31.
View HTML
Toggle Summary Veloxis Pharmaceuticals offentliggør opdateret finanskalendar for 2015
Selskabsmeddelelse nr. 3/2015   Til: NASDAQ OMX Copenhagen A/S                                  Hørsholm, den 21 januar 2015      Veloxis Pharmaceuticals offentliggør opdateret finanskalendar for 2015   Veloxis Pharmaceuticals A/S (OMX: VELO) har i dag offentliggjort opdateret finanskalendar for
View HTML